Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of KPI-121 1% Ophthalmic Suspension Versus Prednisolone Acetate Ophthalmic Suspension 1% for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age

NCT03596723 is registered in ClinicalTrials.gov with Kala Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03596723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03596723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of KPI-121 1% Ophthalmic Suspension Versus Prednisolone Acetate Ophthalmic Suspension 1% for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age
Lead sponsor
Kala Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
July 3, 2018
Completion date
October 18, 2018
Enrollment
2 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ocular inflammation